Alzheon has dosed the first cohort of human volunteers in a Phase 1 single and multiple ascending dose trial of ALZ-507, an oral small molecule developed to inhibit the formation of neurotoxic soluble amyloid oligomers and featuring an APOE4 corrector mechanism.
The company reports that the ALZ-507 IND program demonstrated a favorable nonclinical safety and pharmacokinetic profile that supports once-daily dosing and an oral capsule formulation, and the Phase 1 study will assess safety, tolerability and pharmacokinetics in healthy volunteer participants.
Findings from the trial are expected to guide dose selection and inform formulation strategy for subsequent Phase 2 studies in patients with Alzheimer’s disease, Down syndrome–associated AD and cerebral amyloid angiopathy. ALZ-507 broadens Alzheon’s precision medicine pipeline alongside valiltramiprosate/ALZ-801, an oral agent in Phase 3 development; the company claims ALZ-801 has shown clinical efficacy at the mild cognitive impairment stage and a favorable safety profile with no observed increase in brain vasogenic edema.
The announcement frames ALZ-507 as a next-generation, once-daily oral candidate intended to improve gastrointestinal tolerability and disease-modifying potential.
